SML1949
Synta66
≥98% (HPLC)
동의어(들):
4-Pyridinecarboxamide, N-(2′,5′-dimethoxy[1,1′-biphenyl]-4-yl)-3-fluoro-, GSK1349571A, N-(2′,5′-Dimethoxy[1,1′-biphenyl]-4-yl)-3-fluoro-4-pyridinecarboxamide, S66, Synta 66, Synta-66
InChI key
GFEIWXNLDKUWIK-UHFFFAOYSA-N
SMILES string
O=C(NC1=CC=C(C2=C(OC)C=CC(OC)=C2)C=C1)C3=CC=NC=C3F
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
Application
Synta66 has been used:
- as a Ca2+ release-activated calcium (CRAC) channel inhibitor to study its effects on ORAI isoforms
- as an ORAI1 blocker to study its effects on the entry of Ca2+ in chronic lymphocytic leukemia (CLL) B cells
- as a CRAC blocker to study its effects on the influx of Ca2+ by store-operated Ca2+ entry (SOCE) in enamel cells
Biochem/physiol Actions
A selective SOCE inhibitor that blocks CRAC current (ICRAC) without significant off-target potency or affinity.
Synta66 (S66) is a CRAC (Ca2+ release-activated Ca2+) channel inhibitor that blocks SOCE (store-operated Ca2+ entry) upon Ca2+ depletion from intracellular stores by thapsigargin in human vascular smooth muscle cells (VSMCs) with high potency (IC50 = 26 nM & 43 nM based on maximum Ca2+ level & rate of increase, respectly). Synta66 exhibits no affinity toward a range of receptors and ion channels (e.g. L-type Ca2+ channel) and does not affect TRPC1/5-mediated SOCE or store-operated non-selective cationic current. Leukocytes are reported to be less sensitive to CRAC inhibition by Synta66 (IC50 = 1.76 μM/HL-60, 1 ?M/Jurkat, 1.4 μM/rat RBL).
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Antonio Di Sabatino et al.
Journal of immunology (Baltimore, Md. : 1950), 183(5), 3454-3462 (2009-08-04)
Prolonged Ca(2+) entry through Ca(2+) release-activated Ca(2+) (CRAC) channels is crucial in activating the Ca(2+)-sensitive transcription factor NFAT, which is responsible for directing T cell proliferation and cytokine gene expression. To establish whether targeting CRAC might counteract intestinal inflammation, we
Siaw Wei Ng et al.
The Journal of biological chemistry, 283(46), 31348-31355 (2008-09-23)
Mast cell activation involves cross-linking of IgE receptors followed by phosphorylation of the non-receptor tyrosine kinase Syk. This results in activation of the plasma membrane-bound enzyme phospholipase Cgamma1, which hydrolyzes the minor membrane phospholipid phosphatidylinositol 4,5-bisphosphate to generate diacylglycerol and
Jing Li et al.
British journal of pharmacology, 164(2), 382-393 (2011-05-07)
The aim was to advance the understanding of Orai proteins and identify a specific inhibitor of the associated calcium entry mechanism in vascular smooth muscle cells (VSMCs). Proliferating VSMCs were cultured from human saphenous veins. Intracellular calcium was measured using
Xuexin Zhang et al.
Cell calcium, 91, 102281-102281 (2020-09-09)
The ubiquitous Ca2+ release-activated Ca2+ (CRAC) channel is crucial to many physiological functions. Both gain and loss of CRAC function is linked to disease. While ORAI1 is a crucial subunit of CRAC channels, recent evidence suggests that ORAI2 and ORAI3
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.